4640 Results

People

  1. Saltz
    Saltz
  2. O'Reilly
    O'Reilly
  3. Abou-Alfa
    Abou-Alfa
  4. Kelsen
    Kelsen
  5. Ilson
    Ilson
  6. Kemeny
    Kemeny
  7. Janjigian
    Janjigian
  8. Reidy
    Reidy
  9. Jarnagin
    Jarnagin
  10. D'Angelica
    D'Angelica

Groups

  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)
  7. Epidemiology and Biostatistics (828)
  8. GSK Faculty (793)
  9. Department of Pathology and Laboratory Medicine (723)
  10. Biostatistics Service (661)
  1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis
    Journal Article

    Yamaguchi, N.; Weinberg, E. M.; Nguyen, A.; Liberti, M. V.; Goodarzi, H.; Janjigian, Y. Y.; Paty, P. B.; Saltz, L. B.; Kingham, T. P.; Loo, J. M.; more...
    eLife (2019)

    Fulltext@MSK | Save
  • Current and future aspects of immunotherapy for esophageal and gastric malignancies
    Review

    De Mello, R. A.; Lordick, F.; Muro, K.; Janjigian, Y. Y.
    American Society of Clinical Oncology Educational Book (2019)

    Fulltext@MSK | Save
  • Value-added decisions in oncology
    Review

    Tannock, I.; Presley, C. J.; Saltz, L. B.
    American Society of Clinical Oncology Educational Book (2019)

    Fulltext@MSK | Save
  • Improving health outcomes in pancreatic cancer using animated pancreas patient (APP) visual formats of learning: A National Pancreas Foundation (NPF) patient education initiative
    Meeting Abstract

    Munigala, S.; O'Reilly, E. M.; Alsante, M.; Holt, J. M.; Ko, A. H.; Gelrud, A.
    Pancreas (2019)

    Fulltext@MSK | Save
  • Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients with a germline BRCA mutation and metastatic pancreatic vancer (mPC): Phase III POLO trial
    Meeting Abstract

    Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
    Pancreas (2019)

    Fulltext@MSK | Save
  • APACT: Phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) versus gemcitabine (G) for surgically resected pancreatic adenocarcinoma
    Meeting Abstract

    Ko, A.; Reni, M.; Riess, H.; Pelzer, U.; O'Reilly, E. M.; Winter, J.; Oh, D. Y.; Li, C. P.; Tortora, G.; Chang, H. M.; more...
    Pancreas (2019)

    Fulltext@MSK | Save
  • BEACON: A randomised, phase 3 study of encorafenib and cetuximab +/- binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer patients
    Meeting Abstract

    Wasan, H.; Arkenau, T.; Braun, M.; Samuel, L.; Graham, J.; Kopetz, S.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Yoshino, T.; more...
    British Journal of Cancer (2019)

    Fulltext@MSK | Save
  • Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
    Meeting Abstract

    Yau, T.; Meyer, T.; Kelley, R. K.; Mangeshkar, M.; Cheng, A. L.; El-Khoueiry, A. B.; Abou-Alfa, G. K.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2-locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
    Meeting Abstract

    Yamaguchi, K.; Shitara, K.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D.; Enzinger, P.; Ilson, D.; Kim, S.; Lordick, F.; Shah, M.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2-Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
    Meeting Abstract

    Xu, R. H.; Dongsheng, Z.; Ajani, J.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D.; Enzinger, P.; Ilson, D.; Kim, S.; Lordick, F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save